Cisplatin Combination Chemotherapy in the Treatment of Sixty-four Patients with Advanced Non-Small Cell Lung Cancer
Zhou Shengyu; Feng Fengyi; Zhang Xiangru, et al.(Cancer Institute and Hospital, CAMS & PUMC, Beijing 100021)
(Purpose) To analyse the results of advanced non-small cell lung cancer(NSCLC) treated by MVP regimen(Mitomycin C, Vindesine and Cisplatin), (Methods) Sixty- four patients with advanced NSCLC were treated by MVP regimen,all of them had stage Ⅲ~ Ⅳ disease, and 39 of them were ptimary treatment. There were 42 adenocarcinomas, 15 squamous cell carcinomas, adenosquamous cell carcinomas and 6 not classfied. (Results) The overall response rate(RR) was 32. 8% (21/64), medium response time 4 months, medium survival time 6 months. In 39 Patients with primary treatment, their RR was 41. 0% (16/39), but that of the other patients after multiple course treatments was 20. 0% (5/25), the result of primary treatment was better (P＜0.05). RR of adenocarcinoma with prirnary treatment was 39. 3% (11/28), equasmous cell carcinoma was 16. 7% (1/6), but there was no sighficant difference between them(P＞0. 05 ). In three cisplatin-given methods, the result of cisplatin-given with 60mg/m2 ~80mg/m2 by single administration was better. The major side effects were myelosuppression and gastrointestinal toxicity. [Conclusions] Authors suggest that MVP regimen is the efficacy regimen for the therapy in non-small cell lung cancer. It can be used as the first line treatment regimen, but its serious side effects, espicially leukopenia and thrombocytopenia should be noticed. RR may be improved when the cisplatin is given by single administration with＞ 60mg/m2~ 80mg/m2 dose.